San Antonio Breast Cancer Symposium

Transcription

1 Tuesday, December 9, EDUCATION SESSIONS 2:00 p.m. 5:30 p.m. Management of metastatic HER2 positive disease: optimizing current therapies and an overview of new agents in development - Ballroom B Reconstruction for the high risk patient: challenges of chemotherapy, radiation therapy and patient selection - Ballroom A Mehra Golshan, MD Director, Breast Surgical Services, Triple Negative Adjuvant and neoadjuvant therapy: Current practice & future approaches- - Hall D Director, Breast Oncology Center, Susan F. Smith Center for Women's Cancers, Molecular Heterogeneity Epigenetic heterogeneity in cancer - Ballroom B Kornelia Polyak, MD, PhD Professor of Medicine, Medical Oncology Wednesday, December 10, 8:45 a.m. S1-01: TransCONFIRM: The correlative analysis of breast tumors from patients with advanced hormone receptor positive disease identifies a genetic signature associated with decreased benefit from single agent fulvestrant GENERAL SESSION 1 Hall D Rinath Jeselsohn, MD Page 1

2 Wednesday, December 10, 1:00 p.m. Role of Advocates in Community, Research and Policy SPECIAL FORUM - Ballroom A Director, Breast Oncology Center, Susan F. Smith Center for Women's Cancers, Contralateral Prophylactic Mastectomy: Controversies and Trends CLINICAL SCIENCE FORUM - Hall D Ann Partridge, MD Founder and Director, Program for Young Women with and Director of Adult Survivorship Program, Discovering Rational Combination Therapies Targeting DNA repair in triple negative breast cancer therapy BASIC SCIENCE FORUM - Ballroom B Alan D Andrea, MD Co-Director, Gene Therapy Center 3:30 p.m. The FERGI Phase II Study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo - GENERAL SESSION 2 Hall D POSTER SESSION 1 Halls A-B Enobosarm for the treatment of metastatic, estrogen and androgen receptor positive, breast cancer. Final results of the primary endpoint and current progression free survival P Susan F. Smith Center for Women s Cancers Page 2

3 Effect of margin width on local recurrence in invasive lobular carcinoma treated with multimodality therapy P Otto Metzger, MD Breast Oncology Center Thursday, December 11, POSTER SESSION 2 Halls A-B Variation in the use of mastectomy (MAST) in women with small node negative breast cancer (BC) treated at US academic institutions P Ines Vaz Luis, M.D., M.Sc Decision-making surrounding adjuvant chemotherapy in young women with early stage breast cancer P Shoshana Rosenberg, MD POSTER SESSION 3 Halls A-B 9:30 a.m. P Homologous recombination deficiency (HRD) assay predicts response to cisplatin neoadjuvant chemotherapy in patients with triple negative breast cancer Andrea Richardson, MD, PhD Surgical pathologist P Efficacy of eribulin in patients with invasive lobular carcinoma of the breast: data from a pooled analysis Otto Metzger, MD Breast Oncology Center Page 3

4 4:45 p.m. S4-05: Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response (pcr) rates in triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) or bevacizumab GENERAL SESSION 4 Director, Breast Oncology Center, Susan F. Smith Center for Women's Cancers, PD3-5: Whole exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients with or without prior trastuzumab (T): A correlative analysis of TBCRC003 POSTER DISCUSSION 3 Nikhil Wagle, MD Medical Oncologist Friday, December 12, POSTER SESSION 4 Halls A-B Page 4 P : MECP2 is a frequently amplified oncogene and potential therapeutic target in TNBC Daniel P. Silver, MD, PhD Assistant Professor of Medicine, Medical Oncology/Cancer Biology P : Clinical, biochemical, and genomic predictors of trastuzumab-related cardiotoxicity: Results of CATS Shom Goel, MD Goldfarb-Rudkin Breast Oncology Fellow Dana Farber Cancer Institute P Prospective characterization of HER2- positive circulating tumor cells in patients with HER2-negative metastatic breast cancer

5 POSTER SESSION 5 P : Clinical activity of abemaciclib, an oral cell cycle inhibitor, in metastatic breast cancer - POSTER DISCUSSION 5: Targeting the PI3K Pathway- Ballroom A Sara Tolaney, MD, MPH Attending Physician, Medical Oncology Saturday, December 13, POSTER SESSION 6 P : Clinical outcomes of triple negative inflammatory breast cancer treated with contemporary anthracycline and taxane preoperative therapy support further investigation of therapeutic targets P : Risk factors for developing inflammatory breast cancer: Unique trends among a single patient population 9:00 a.m. Adjuvant and neoadjuvant THE YEAR IN REVIEW - Hall D Harold J. Burstein, MD, PhD Susan F. Smith Center for Women s Cancers at Dana-Farber Cancer Institute Page 5